A Study to Compare the Effectiveness of Two Vonoprazan-Based Treatment Options for Helicobacter pylori Infection

Comparison of Vonoprazan dual therapy with Vonoprazan Bismuth-based triple therapy in Helicobacter pylori eradication A Randomized Controlled Trial - PILL-B Trial

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2026/01/100661

Enrollment

140

Registered

2026-01-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K296- Other gastritis

Interventions

Intervention1: Vonoprazan Bismuth Based triple Therapy: Vonoprazan 20 mg BD + Amoxicillin 750mg TDS + Bismuth subcitrate 240mg BD Duration: 14 days Control Intervention1: Vonoprazan Dual Therapy: Vono

Eligibility

Inclusion criteria

Inclusion criteria: Adults aged 18 to 70 years Confirmed H pylori infection by Rapid Urease Test Treatment Naive for H pylori

Exclusion criteria

Exclusion criteria: Known Allergy to study drugs Previous H pylori eradication therapy Pregnancy or lactation Patients on NSAIDS Severe hepatic or renal impairment

Design outcomes

Primary

Measure	Time frame
To compare the eradication rates of H. pylori between Vonoprazan Dual therapy and Vonoprazan bismuth based Triple therapyTimepoint: 6 weeks	—

Secondary

Measure	Time frame
1)Adherence to treatment Regimen 2)To evaluate adverse drug events Timepoint: 6 weeks	—

Countries

India

Contacts

Public ContactHarrison Gabriel G B

Government Kilpauk Medical college

ddhdkmc@gmail.com9443206141

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026